Medication and atypical brain maturation in psychosis are associated with long-term cognitive decline and symptom progression

Claudio Alemán-Morillo[1], Natalia García-San-Martín[1], Richard AI Bethlehem[2], Lena Dorfschmidt[3,4], María Alemany-Navarro[5], Patricia Segura[1], Alessia Pasquini[1], Manuel Muñoz-Caracuel[5], Manuel Canal Rivero[5], Jakob Seidlitz[3,4,7,8], Rosa Ayesa-Arriola[9], Javier Vázquez-Bourgon[9], John Suckling[10], Miguel Ruiz-Veguilla[6], Benedicto Crespo-Facorro[6], Rafael Romero-García[1,10,11].

Author affiliations:

[1]Department of Medical Physiology and Biophysics, University of Seville; Seville, Spain.

[2]Department of Psychology, University of Cambridge; Cambridge, UK.

[3]Department of Child and Adolescent Psychiatry and Behavioral Science, The Children's Hospital of Philadelphia; Philadelphia, PA, USA.

[4]Lifespan Brain Institute, The Children's Hospital of Philadelphia and Penn Medicine; Philadelphia, PA, USA.

[5]Translational Psychiatry Group, Instituto de Biomedicina de Sevilla (IBiS)-CSIC, Spain; CIBERSAM, ISCIII, Spain.

[6]Mental Health Service, Virgen del Rocío University Hospital; Seville, Spain. Instituto de Biomedicina de Sevilla (IBiS) HUVR/CSIC/University of Seville / CIBERSAM, ISCIII; Seville, Spain.

[7]Department of Psychiatry, University of Pennsylvania, Philadelphia, PA, USA.

[8]Institute for Translational Medicine and Therapeutics, University of Pennsylvania, Philadelphia, PA, USA

[9]Department of Psychiatry. Marqués de Valdecilla University Hospital, IDIVAL, School of Medicine, University of Cantabria; Santander, Spain.

[10]Department of Psychiatry, University of Cambridge; Cambridge, UK.

[11]Instituto de Biomedicina de Sevilla (IBiS) HUVR/CSIC/University of Seville / CIBERSAM, ISCIII; Seville, Spain.

Correspondence to: Rafael Romero García
Full address: Avda. Doctor Fedriani S/N, 41009, Seville (Spain)
Telephone: +34 954551768
E-mail: rr480@cam.ac.uk

Running title: Centiles and clinical outcomes in psychosis.

Keywords: Psychosis, normative modelling, centiles, cognition, longitudinal MRI, schizophrenia

ABSTRACT

Background: Clinical progression during psychosis has been closely associated with grey matter abnormalities resulting from atypical brain development. However, the complex interplay between psychopathology and heterogeneous maturational trajectories challenges the identification of neuroanatomical features that anticipate symptomatic decline.

Aims: To investigate cortical volume longitudinal deviations in FEP using normative modelling, exploring their relationship with long-term cognitive and symptomatic outcomes, as well as their cytoarchitectural and neurobiological underpinnings.

Methods: We collected MRI, cognitive, and symptomatic data from 195 healthy controls and 357 drug-naïve or minimally medicated FEP individuals that were followed up 1,3,5 and 10 years after the first episode (1209 MRI scans and assessments in total). Using normative modelling, we derived subject-specific centile scores for cortical volume to investigate atypical deviations in FEP and their relationship to long-term cognitive and symptomatic deterioration. The resulting centile association maps were further characterized by examining their cytoarchitectural and neurobiological attributes using normative atlases.

Results: FEP centiles showed a widespread reduction at treatment initiation, with longitudinal analysis showing an increase during treatment time, indicating convergence toward normal maturation trajectories. Interestingly, this effect was reduced in highly medicated individuals. Additionally, we found that cognitive impairments experienced during early FEP stages worsened under long-term medication. Positive symptomatology was negatively associated with regional centiles, and individuals with higher centiles benefited most from treatment. Cytoarchitectural and neurobiological analyses revealed that regional centiles related to FEP,

as well as to symptomatology, were associated with specific molecular features, such as regional serotonin and dopamine receptor densities.

Conclusions: Collectively, these findings underscore the potential use of centile-based normative modelling for a better understanding of how atypical cortical development contributes to the long-term clinical progression of neurodevelopmental conditions.

INTRODUCTION

Atypical brain structure in FEP

First Episode Psychosis (FEP) is characterised by heterogeneous clinical presentations [1], temporal progression [2], and responses to medication [3]. Cross-sectional MRI studies consistently report alterations in frontal and temporal cortices [4], with some identifying changes in insular [5], parietal [6], and occipital regions [7]. Longitudinal studies have additionally revealed progressive cortical deterioration in FEP, especially in frontal and temporal regions, over 1 [8], 2–3 [9], 5 [10], and 10 years [11]. Despite these findings, the complex interplay between brain development, sex, and neurodevelopmental pathophysiology complicates the disentanglement of their individual contributions to brain structure and function. Normative modelling addresses this by creating “growth charts” of brain development [12], allowing individuals to be ranked and assigned centile scores based on deviations from expected neurotypical trajectories. This approach has been used to identify abnormal structural subtypes in autism [13] and deviations in ADHD symptoms [14]. In psychosis, normative modelling reveals deviations in cortical thickness in temporal areas during high-risk states [15] and across the cortex in FEP [16], with these deviations diminishing during treatment [17].

Brain structure and clinical outcomes

MRI studies have also extensively explored the clinical presentation of FEP, linking positive symptoms, such as hallucinations and delusions, to thinning in frontal [18] and temporal [19] cortices. Conversely, negative symptoms, like anhedonia and social withdrawal, are associated with reduced orbitofrontal thickness [20]. The effects of antipsychotics on brain structure remain debated, with studies reporting both grey matter reductions [21] and increased regional thickness [22]. Cognitive decline in FEP has been observed prior to the onset of psychosis [23], while post-onset trajectories vary, with reports of stabilization [24], decline [25], or improvement [26]. Normative modelling has shown neurocognitive delays in youth reporting psychotic symptoms [27], but the long-term impact of antipsychotics on cognition remains uncertain [28].

Regional vulnerability to atypical development

The spatial patterns of cortical deterioration shared across psychiatric and neurological conditions have been interpreted as a reflection of differential regional vulnerability to pathology [29]. Under this hypothesis, cortical vulnerability to psychosis-related deterioration may reflect regional differences in cellular composition, neurotransmitter receptors, and metabolism [29], with regions of high serotonin and acetylcholine receptor density showing greater atypical deviations [30]. In this study, we hypothesize that FEP patients exhibit atypical brain development influenced by treatment and medication, which impacts cognitive and symptom progression. We analysed baseline and 10-year follow-up longitudinal data to explore associations between brain deviations, clinical diagnosis, medication, cognition, and symptoms. Using cytoarchitectonic and neurobiological atlases, we additionally characterized psychosis-related brain deviations based on neurotransmitters, cell types, microstructure, and metabolism.

METODOLOGY

Subjects

MRI and phenotypic data were collected from healthy controls (n = 195; 120 males; mean age = 29.1 ± 7.63 years) and individuals with first-episode psychosis (FEP; n = 357; 213 males; mean age = 29.8 ± 8.76 years), who were followed longitudinally. Follow-up assessments were conducted at baseline (193 controls, 333 FEP), 1 (62 controls, 96 FEP), 3 (51 controls, 136 FEP), 5 (76 controls, 70 FEP), and 10 (91 controls, 101 FEP) years (See Fig. S1 and S2 for flow diagram for study participants and alluvial diagram of attrition).

Recruitment was conducted through the Program for Attention to the Initial Phases of Psychoses (PAFIP) at Marqués de Valdecilla University Hospital and Valdecilla Health Research Institute (IDIVAL) in Spain. The authors assert that all procedures contributing to this work comply with the ethical standards of the relevant national and institutional committees on human experimentation and with the Helsinki Declaration of 1975, as revised in 2013. All procedures involving human subjects were approved by the CEIC-Cantabria (clinical trial numbers NCT0235832 and NCT02534363) and the Ethic committee of the University of Seville (2024-2534). Following a comprehensive explanation of the study, each participant provided written informed consent prior to enrolment. Participants in the clinical group met DSM-IV criteria for schizophrenia spectrum disorders, including schizophrenia (n=156), schizophreniform disorder (n=99), schizoaffective disorder (n=6), brief psychotic disorder (n=48), and psychosis not otherwise specified (n=24). See a full list of inclusion and exclusion

122 criteria in Supplementary Methods. Detailed demographic and clinical information stratified by
123 sex and diagnosis are provided in Supplemental Material (Figs. S3-S4 and Tables S1-S4).

124 Cognitive and symptom assessment

125 Cognition was assessed for the following domains: (1) verbal memory: Rey Auditory Verbal
126 Learning Test (RAVLT) long-term recall score; (2) visual memory: Rey Complex Figure test
127 (RCFT) long-term recall score; (3) motor dexterity: grooved pegboard (GP), time to complete
128 with dominant hand; (4) executive functions: Trail Making Test part B (TMTb); (5) working
129 memory: WAIS III-Backward Digits (BD) total score; (6) speed of processing: WAIS III-Digit
130 Symbol (DS) standard total score; (7) attention: Continuous Performance Test Degraded-
131 Stimulus (CPT-DS), the total number of correct responses [31]. For each cognitive test, z-scores
132 were computed by subtracting the mean and dividing by the standard deviation of the control
133 group's scores. Overall cognitive functioning was calculated as the mean z-score across the
134 seven cognitive tests for each individual. FEP participants were also assessed using the Scale
135 for the Assessment of Negative Symptoms (SANS, 21 items), Scale for the Assessment of
136 Positive Symptoms (SAPS, 30 items), and Brief Psychiatric Rating Scale (BPRS, 24 items).

137 Principal Component Analysis (PCA) was conducted on cognition and symptom items to
138 compare with average scores used in the calculations. Sensitivity analyses examined (i) the
139 impact of cannabis use and (ii) study dropout on cognitive and symptom measures.
140 Psychological evaluations were performed by experienced psychiatrists using the structured
141 clinical interview for DSM-IV, with diagnoses confirmed at 6 months.

142 MRI acquisition and volume extraction

143 Structural MRI scans were acquired using a 1.5T General Electric SIGMA System (GE,
144 Milwaukee, USA) and a 3T Philips Medical Systems MRI scanner (Achieva, Best, The
145 Netherlands) equipped with an 8-channel head coil. Baseline and follow-up scans for each
146 individual were consistently conducted using the same machine. The imaging protocol
147 included a T1-weighted image that underwent visual inspection for QC. The parameters for
148 1.5T were: TE=5ms, TR=24ms, NEX=2, rotation angle=45°, FOV=26×19.5cm, slice
149 thickness=1.5mm, voxel size=1.02x1.02x1.5 mm, and a matrix of 256×192, whereas for 3T
150 were TE = 3.7ms, TR=8.2ms, flip angle=8°, acquisition matrix=256×256, voxel size=0.94x0.94x1
151 mm and 160 contiguous slices. The longitudinal pipeline of FreeSurfer 7.0.0 (recon-all) was
152 used to estimate global cortical volume and regional volume of each region defined in the

Desikan–Killiany atlas (34 regions per hemisphere). One regional outlier (>5 SD from the mean) was excluded. Raw regional volumetric data from both scanners were harmonised using ComBatLS preserving age, sex and diagnosis variance [32].

Regional volumetric centile estimation

We leveraged the cross-sectional normative trajectories established by the BrainChart study, which benchmarked cortical volumes from the Desikan-Killiany atlas against data from over 100,000 neurotypical individuals [12]. Based on these trajectories, we computed out-of-sample centile estimates for our longitudinal sample, using the control cohort to account for scanner-related offsets (https://github.com/brainchart/Lifespan). Following the Bethlehem et al. 2022 pipeline, the volumetric values of left and right homologous regions were averaged to obtain a single measure per region, and centiles were subsequently computed from these averaged values. Age-normed, sex-stratified, and site-corrected deviations were derived and expressed as centile scores. Centile scores represent the relative position of an individual's grey matter volume with respect to normative lifespan trajectories. Scores below 0.5 indicate volumes lower than the median for age- and sex-matched individuals, whereas scores above 0.5 indicate volumes higher than the median. Residual effects of site or motion (Euler index) on centile scores were assessed using ANOVA.

Baseline analyses using multiple regression

To evaluate the impact of FEP diagnosis on baseline centiles, a multiple regression was performed for each cortical region using the following model:

$$regional\ centile \sim 1 + diagnosis + sex + age\ of\ inclusion + etiv \quad (1)$$

where diagnosis was a binary variable (control vs. FEP), age of inclusion referred to participants' age at the first scan, and etiv represented cranial volume residuals after age and sex correction (which allowed us to account for anthropometric factors using a single variable). Age of inclusion and etiv were Z-scored prior to regression. All p-values were corrected for multiple comparisons across regions using false discovery rate (FDR).

Longitudinal analyses using Mixed Modelling

The longitudinal effects of disease and medication on centiles and clinical outcomes were analysed using Mixed Modelling over 1,209 assessments (195 controls, 357 FEP). Antipsychotic medication exposure was assessed at each visit (Fig. S5) and converted into chlorpromazine equivalents (CPZ-equivalents) [33].

Linear Mixed Modelling for predicting regional centiles as a function of disease progression and treatment

Linear Mixed Modelling (LMM) was used to assess the impact of time from the first scan (for controls) and time from treatment initiation (for FEP), collectively referred to as time, in regional centiles. The contribution of age was separated between age of inclusion and time to be able to capture specific interaction effects between treatment time, medication and centiles trajectory in patients:

$$regional\ centile \sim 1 + diagnosis + sex + age\ of\ inclusion + etiv + medication + time + time\ x\ diagnosis + medication\ x\ time + (1|\ subject)\ (2)$$

where, in addition to the aforementioned variables, we also considered: medication at the time of MRI acquisition (antipsychotic dose in CPZ-equivalents), time x diagnosis (interaction between time and diagnosis) and medication x time (interaction indicating whether medication alters the effect of treatment time on centiles) and "1|subject" as a random intercept to account for random subject-specific offsets overall. Age of inclusion, etiv, medication and time were Z-scored prior to regression.

Sensitivity analyses repeated these models using raw regional volumes instead of centiles as the dependent variable.

LMM for predicting cognitive functioning as a function of treatment and regional centiles

After exploring the effects of disease and treatment on centiles, we evaluated how these factors relate to overall cognitive functioning:

$$cognition \sim 1 + diagnosis + sex + age\ of\ inclusion + etiv + medication + time + centile + time\ x\ diagnosis + medication\ x\ time + centile\ x\ diagnosis + centile\ x\ time + (1|\ subject)\ (3)$$

Models were fitted independently for each region, resulting in one parameter estimate per region and covariate. For visualization, a cortical map was generated for each covariate to summarize the regional patterns of association. All p-values were corrected for multiple comparisons across regions using FDR.

Generalized Mixed Modelling for predicting clinical symptomatology as a function of treatment and regional centiles

Symptomatology (BPRS, SAPS, and SANS scores) was modelled as:

$$symptoms \sim 1 + sex + age\ of\ inclusion + etiv + centile + time + medication + medication\ x\ time + centile\ x\ medication + centile\ x\ time + (1|\ subject)\ (4)$$

Generalized Mixed Models with a Poisson distribution were used due to the count-like nature of symptom scores and their alignment with exponential decay patterns. Separate analyses were conducted for each region and for each psychometric scale.

Furthermore, for each scale, we conducted a mediation analysis to determine whether the association between medication and symptoms was mediated by the regional centile most strongly associated with symptoms. A bootstrap with 10,000 resamples was used to test for the presence of average direct effect (ADE), average causal mediation effect (ACME) and the total effect (ADE+ACME).

Cytoarchitectural characterization of centile associations

Cortical centiles associated with phenotypic variables (diagnosis, medication, BPRS, SAPS, SANS) were mapped onto the cortical hierarchies defined by Mesulam atlas (unimodal, paralimbic, idiotypic, heteromodal, https://github.com/ucam-department-of-psychiatry/maps_and_parcs, Table S5**,** [34]. ANOVA tests and Tukey post-hoc analyses were used to identify differential distributions of centile associations across Mesulam areas.

Neurobiological mapping of centile associations

Centile-phenotypic associations were also profiled using 46 molecular and microarchitectural maps derived from MRI/PET studies, expanding on the methodology presented on [35] and implemented at https://github.com/netneurolab/neuromaps and https://github.com/RafaelRomeroGarcia/NeurobiologyCentilesPsychosis. These maps included: neurotransmitter receptors (5-HT_{1A}, 5-HT_{1B}, 5-HT_{2A}, 5-HT_4, 5-HTT, H_3, D_1, D_2, DAT, NET, $\alpha_4\beta_2$, VAChT, CB_1, M_1, MOR, $mGluR_5$, NMDA, GABA), cell types (astrocytes, endothelial cells, microglia, oligodendrocytes, oligodendrocytes precursors, excitatory neurons, inhibitory neurons), cortical layers (I-VI), microstructural properties (synapse density, neurotransmitter PC1, gene expression PC1 [which is highly driven by cell types [36]], cortical thickness, myelin), metabolism (glycolytic index, cerebral blood flow, cerebral blood volume, oxygen metabolism and glucose metabolism), cortical expansion (evolutionary expansion, developmental expansion, allometric scaling from Philadelphia Neurodevelopmental Cohort, allometric scaling from National Institutes of Health). See Table S6 for the full list of neurobiological features included in the analysis.

238 Principal Component – Canonical Correlation Analysis (PC-CCA;
239 https://github.com/RafaelRomeroGarcia/cca_pls_toolkit) was used to identify combinations of
240 neurobiological features that best explained centile-phenotypic associations [37]. PC-CCA
241 reduces data dimensionality using PCA to minimize overfitting and then identifies the linear
242 combination (weighted sum of loadings) of the neurobiological maps that best predicts the
243 inter-regional variance of each centiles-phenotypic association map. Statistical significance was
244 evaluated using spatial autocorrelation-preserving permutation tests (spin tests;
245 https://github.com/frantisekvasa/rotate_parcellation) with 10,000 parcellation-specific
246 rotations. To validate the multiple regression patterns identified with PC-CCA, we conducted a
247 sensitivity analysis with Partial Least Squares (PLS). PLS maximizes the covariance between the
248 two variable sets, providing a robust alternative when collinearity might affect the canonical
249 solution [37].

250 RESULTS

251 Impact of diagnosis and treatment on centiles

252 Using multiple regression on baseline data, FEP patients demonstrated significantly lower total
253 grey matter volume centiles compared to controls ($T = -6.20$, $p < 10^{-8}$), but no reductions in
254 total white matter centiles ($T = 1.67$, $P = 0.095$, Table S7**;** Table S8 for model fit estimates).
255 Consistently, regional analyses showed widespread cortical reductions in centiles associated
256 with diagnosis (**Fig. 1**, Baseline). Covariates such as age of inclusion and etiv correlated
257 positively with centiles, while females exhibited lower centiles (**Fig. 1**, Baseline). Effect sizes
258 and FDR-corrected significance levels are fully provided in the supplementary data. Centiles
259 were not significantly associated with motion artifacts quantified using the Euler index
260 (Spearman's rho = -0.016, $P = 0.587$; Fig. S6). As a sensitivity analysis, we recalculated the
261 model including an age of inclusion x diagnosis interaction term, which revealed that the
262 positive effect of age of inclusion on centiles was significantly attenuated in patients ($T = –$
263 2.73, $P = 0.006$).

264 Longitudinal analyses using LMM over 10 years revealed that longer treatment duration in FEP
265 patients was associated with increased global centile scores, progressively approaching
266 normative values ($T = 4.02$, $p < 10^{-4}$; Table S9). Regionally, significant diagnosis-centile
267 associations were observed across the whole cortex (**Fig. 1**, longitudinal). The main effect of
268 time showed both positive and negative correlations with centiles; however, the time × FEP
269 interaction revealed a generalized positive association (see Fig. S7A for an illustration of this
270 interaction). Medication (CPZ-equivalent) was negatively associated with centiles, showing also

271 a negative interaction with time. Despite the robust effect of medication, substantial inter-
272 subject variability in centiles persisted between individuals with low versus high medication
273 doses (Fig. S8).

274 These LMM analyses were repeated using raw volumes instead of centiles. As illustrated in Fig.
275 S9, the principal age- and time-related negative association captured the expected decline in
276 regional volume with aging. Consistent with the centile results, this model also indicated a
277 positive time x FEP interaction, which was attenuated by medication.



278

Fig. 1. Associations between phenotypic data and covariates with regional centiles. **Top panel.** Contribution of each variable to the multiple regression of baseline data. **Bottom panel** Contribution of each variable to the LMM of longitudinal changes in centiles (up to 10 years follow-up). Scale represents t-values associated with each regression parameter. Non-significant contributions ($P_{fdr} \geq 0.05$) are depicted with desaturated colours.

Regional centiles associated with cognitive impairment

Principal component analysis (PCA) of cognitive subscales revealed a first PC explaining 45.3% of the variance, with similar weights across the seven subscales (Table S10), so for simplicity, the mean score was used in subsequent analyses. Cognitive function was negatively associated with FEP diagnosis (**Fig. 2**, diagnosis) but did not correlate with regional centiles (**Fig. 2**, centile - psychosis interaction). Accordingly, the high individual variability limits reliable subgrouping based on centile trajectories (Fig. S10). The observed positive effect of medication, together with the negative medication x time interaction, indicates that the initial therapeutic benefits are attenuated with prolonged treatment (illustrated in Fig. S7B). As a sensitivity analysis, models were repeated by categorizing individuals as low-medicated (CPZ ≤ 300) or highly medicated (CPZ > 300). Interestingly, the global grey matter volume centile showed a weak but significant association with cognitive performance in patients (P=0.04, Table S11). Time had a negative impact on cognition among highly medicated individuals (β_{time}- $\beta_{time\ x\ high\text{-}medication}$ =0.13 - 0.21 = –0.08; Table S11).



Fig. 2. Associations between phenotypic data, covariates and centiles with cognitive performance. Contribution of each variable to the LMM of longitudinal changes in cognition (up to 10 years follow-up). Scale represents t-values associated with each regression parameter. Non-significant contributions ($P_{fdr} \geq 0.05$) are depicted with desaturated.

Regional centiles associated with symptomatology

Treatment time correlated negatively with BPRS, SAPS, and SANS scores, indicating symptom reduction over time (**Fig. 3**; see Table S8 for model fit estimates). Medication was associated with reductions in BPRS and SAPS scores but increased SANS scores, likely due to pharmacological specificity for positive symptoms. A positive medication x time interaction

309 indicates that symptom improvement with time was less pronounced in highly medicated
310 patients. Positive symptoms (SAPS) were negatively associated with centiles, particularly
311 overlapping with BPRS, whereas SANS showed a weak correlation with centiles. Younger age at
312 onset was linked to more severe positive symptoms (SAPS). The sensitivity analysis comparing
313 low- versus highly medicated patients revealed that, although attenuated, the effect of time
314 on symptoms remained positive in the highly medicated group (Table S11). No significant
315 differences were observed in cognitive or symptom scores between cannabis users and non-
316 users (Table S12) or between participants who completed the study and those who dropped
317 out (Table S13).

318 Additionally, mediation analyses were performed to examine the potential mediating effects
319 of centiles and time on the association between medication and symptom severity. No
320 evidence of centile mediation was observed at treatment initiation; however, significant long-
321 term mediation effects were identified. Specifically, the association between medication and
322 symptoms was fully mediated by the insula for SAPS (β=0.15, CI:[0.04,0.27]) and partially
323 mediated by the pars orbitalis cortex for SANS (β=-0.05, CI:[-0.11,-0.01], Fig. S11).



324

325 **Fig. 3.** Associations between phenotypic data, covariates and centiles with symptomatology.
326 Contribution of each variable to the GMM of longitudinal changes in BPRS, SAPS and SANS

327 (each column represents different models). Scale represents the Wald z-statistic associated
328 with each regression parameter. Non-significant contributions (P_{fdr}≥0.05) are depicted with
329 desaturated colours.

330 Cytoarchitectural and neurobiological characterization of FEP-related regional 331 centiles

332 Using the Mesulam cytoarchitectonic atlas [34], we characterized regional associations between
333 centiles, cognition, and symptoms. Centiles linked to BPRS or SANS did not show a preferential
334 topographic Mesulam distribution. However, SAPS displayed significantly stronger negative
335 associations in paralimbic regions compared with idiotypic areas (ANOVA, Post-hoc Tukey, P_{fdr}
336 <0.05, **Fig. 4A**). PCA-CCA was used to capture associations between neurobiological data from
337 normative individuals [35] and centiles related to clinical outcomes. Neurobiological mapping
338 revealed that regions associated with FEP diagnosis (Fig. 1) co-located with areas rich in
339 neurotransmitters such as 5-HT_{1B}, 5-HT_{2A}, 5-HT_6, as well as neurons and metabolic features
340 (P=0.004, **Fig. 4B**, negative loadings). Conversely, FEP diagnosis-related regions were
341 associated with lower glial cell densities and 5-HT_{1A} neurotransmitter levels (positive loadings).
342 Neurobiological mapping for regions negatively impacted by medication was not significant.

343 Neurobiological features were significantly co-located with the centile-symptoms associations
344 (**Fig. 4C**). Specifically, centiles associated with BPRS co-located with serotonin 5-HT_{1A}, D_2, and
345 norepinephrine transporters, as well as with glial cells (P=0.009). Regions showing negative
346 correlations between centiles and BPRS (i.e. associated with symptom improvement) were co-
347 located with 5-HT_{1B}, GABA, NMDA receptors, inhibitory neurons, myelin, developmental
348 expansion and allometric scaling. Centiles associated with SAPS recovery were co-located with
349 5-HT_{1A}, 5-HT_4, cannabinoid receptors, D_2, norepinephrine transporters, glia and cortical
350 thickness (P=0.012). Centiles correlated with SANS were co-located with 5-HT_4, cortical
351 thickness and metabolism (P= 0.01).

352 Collectively, these results reveal a significant co-location of atypical brain maturation in FEP
353 with specific neurobiological factors, suggesting that they may play an important role in
354 shaping the structural vulnerability to FEP symptomatology. Consistency analyses using PLS
355 instead of PCA-CCA yielded highly similar neurobiological loading estimates (all r-values > 0.78;
356 Fig. S12).



Fig. 4. Cytoarchitectural and neurobiological characterisation of FEP-related centiles. **A)** Distribution of t-values shown in Fig. 3 across the four cortices delineated in the atlas of Mesulam. Each dot represents a brain region in the Desikan-Killiany atlas. **B)** Neurobiological maps co-located with the diagnosis-centile and medication-centile associations. Positive loadings indicate neurobiological features that are co-located with regions where centiles were positively associated with the variables of interest (in this case, diagnosis and medication). Conversely, negative loadings indicate co-location with regions negatively associated with the variable of interest. **C)** Neurobiological maps co-located with the association between centiles

366 and clinical outcomes (BPRS SAPS, and SANS). "N.S." denotes non-significant models
367 (P_{fdr}≥0.05). For significant models, only significant (P_{fdr}<0.05) loadings are displayed.

368 DISCUSSION

369 In this study, we examined cortical volume deviations using normative centiles models in both
370 neurotypical and FEP participants scanned over the course of 10 years. Our findings indicated
371 that FEP participants had lower regional centiles than controls in multiple cortical areas, a
372 difference that decreased in intensity over the treatment period. However, this convergence
373 between patients and controls was less pronounced in those who were highly medicated.
374 Psychotic symptomatology was negatively correlated with centiles co-located with regions
375 with high serotonin receptor densities. These results highlight the value of normative
376 approaches for better understanding the long-term relationship between cortical maturation
377 and clinical profiles in psychosis.

378 Our normative analysis revealed atypical developmental values in FEP patients who exhibited a
379 generalised reduction in regional centile scores [16]. Previous studies have extensively reported
380 reductions in cortical volume and thickness at different stages of psychosis-related conditions
381 [5,7,16]. As shown by the ENIGMA consortium, although frontal and temporal cortices are the
382 regions showing the strongest effect sizes when compared to normative controls,
383 schizophrenia is also characterised by a generalised reduction over the whole cortex [38].
384 Nevertheless, a major challenge in traditional case-control studies is the lack of personalised
385 metrics capable of detecting individuals with atypical neurodevelopment. Conversely,
386 normative modelling leverages data from thousands of individuals for identifying participants
387 with abnormal trajectories. Using this approach, Worker et al. 2023 [16], demonstrated that a
388 large and widespread number of extreme negative deviations in cortical thickness centiles
389 among FEP exist, revealing that this condition is characterised not only by a diminished group-
390 average cortical thickness but also by specific individuals that exhibit severe thickness
391 reductions.

392 The combination of normative modelling with long-term longitudinal MRI revealed that
393 centiles increased during the treatment period of FEP participants. These findings indicate that
394 grey matter reductions are more pronounced during the early stages of psychosis [39], whereas
395 the age-related volume decreases observed in controls are less pronounced in late psychosis
396 [22]. Berthet et al. (2025) [17] also reported this trend toward a reduced difference over time
397 between controls and FEP patients when investigating cortical thickness using normative
398 modelling. Since this study did not include untreated patients, we cannot disentangle the

399 specific effects of treatment from the natural course of the disease and potential late effects
400 of neurodegenerative pathogenesis [40]. Medication has been previously associated with grey
401 matter loss [41], specifically attributed to caspase-3-mediated neurotoxicity [42]. In this line, we
402 also found that high medication doses were associated with generalized cortical reduction. As
403 suggested by Fusar-Poli et al. 2013 metanalysis [43], long-term GM reductions may be the
404 consequence of the cumulative exposure to the antipsychotics, a finding also supported by
405 other studies [21].

406 While describing the anatomical alterations related to the progression and treatment of
407 psychosis is of great interest, understanding how these changes impact patients' cognitive
408 functionality is of crucial clinical importance. We reported reduced cognitive abilities in drug-
409 naïve and minimally medicated FEP participants immediately after the onset, suggesting that
410 impairment occurs even before the first episode [23]. Cognitive functionality also improved
411 throughout the treatment, indicating that while medication targets positive symptoms, it may
412 also lead to cognitive improvement, albeit as an indirect effect. [23]. Previous studies have also
413 demonstrated cognitive improvement in patients after one [44] or three [45] years of antipsychotic
414 treatment. Nevertheless, our LMM additionally found that medication influenced the
415 association between treatment duration and cognitive function, leading to an attenuation of
416 cognitive recovery over time for patients with higher medication doses. In line with this
417 observation, Kawai et al. 2006 [46] demonstrated that dose-reductions lead to improvements in
418 cognitive performance in a limited sample of individuals treated with multiple conventional
419 antipsychotics.

420 Unsurprisingly, treatment yielded a positive effect on FEP-related symptomatology. As
421 expected, both time and medication primarily had an impact on positive symptoms.
422 Conversely, time had a positive but weaker effect on the reduction of negative symptoms.
423 Despite the fact that medication, especially first-generation antipsychotics, does not alleviate
424 negative symptoms, meta-analyses of placebo-control trials have indeed revealed that most
425 treatments can help reduce negative symptomatology [47]. Nevertheless, here, we observed
426 opposite trends in the model slopes of time (negative) and medication (positive) with SANS,
427 indicating that heavily medicated individuals do not experience negative symptoms
428 improvements over time. This may reflect the diverse and distinct recovery trajectories of
429 illness, with a significant proportion of patients experiencing relapse and showing no
430 improvement in negative symptoms [48]. FEP symptomatology was also associated with regional
431 volumes, with higher centiles values being associated with lower positive symptoms. Similarly,
432 previous studies have associated positive symptoms with cortical alterations in prefrontal,

433 temporal and parietal areas [19]. Conversely, negative symptoms exhibited a weak correlation
434 with centiles, suggesting that while treatment and medication may provide moderate
435 improvement in this domain, these symptoms remain relatively stable and do not significantly
436 influence cortical plasticity. However, further placebo-controlled trials will be necessary to
437 elucidate this [48].

438 Neurobiologically, serotonin neurotransmitters were predominantly present in regions
439 associated with psychosis diagnosis. This may be related with the role of this neurotransmitter
440 mediating the effect of antipsychotic medication which affects mood and cognitive function [49].
441 We also reported differences in centile associations across receptor subtypes such as $5HT_{1A}$
442 and $5HT_{2A}$ which could be a reflection of its complex role in psychosis [50]. Additionally, the co-
443 location of dopamine receptors in regions associated with symptoms suggests a potential
444 pathway whereby elevated levels of antipsychotic medications disproportionately affect
445 dopaminergic regions. Moreover, diagnosis and symptom-related centiles were not only
446 associated with neuronal density maps but also with glial cells, indicating a potential
447 involvement of immunological and inflammatory risk factors [51].

448 **Limitations**

449 Several limitations must be acknowledged. Firstly, the primary inclusion criterion was the
450 diagnosis of FEP at baseline, regardless of subsequent follow-up diagnoses, which
451 predominantly included schizophrenia but also other psychotic disorders. Secondly, the use of
452 CPZ-equivalents provides a simplified representation of the heterogeneous antipsychotic
453 treatments across the sample, allowing us to capture the overall medication effect with a
454 single parameter. However, different classes of antipsychotics may have differential effects on
455 centiles and clinical outcomes. Including all drug-specific doses was not feasible, as this would
456 substantially increase the number of variables and the risk of overfitting. Finally, higher
457 medication doses were generally prescribed to individuals with more resistant positive
458 symptoms. However, these prescriptions were influenced by factors such as age of onset and
459 treatment duration, complicating the disentanglement of individual contributions in the
460 models.

461 This brain-wide association study (BWAS) demonstrates that centiles are associated with
462 clinical outcomes in FEP. Nevertheless, growing evidence highlights important concerns: BWAS
463 are susceptible to inflated effect sizes and low replication rates unless samples include
464 thousands of individuals [52]. Recent findings by Kang et al. 2024, have shown, however, that
465 longitudinal designs can substantially improve replicability [53]. In this study, participants were

comprehensively assessed over a 10-year period. While replication gains plateau after the first follow-up, particularly for structural markers, which exhibit limited within-subject variability, longitudinal assessments remain valuable for capturing the pronounced phenotypic decline in cognition and symptoms over time in FEP. Importantly, this high within-subject phenotypic variability is critical for enhancing replicability, especially when modelled separately from between-subject variability [53], as implemented here.

We aimed to maintain the models as parsimonious as possible. With 552 participants, up to 11 fixed variables and at least 449 degrees of freedom, the resulting balance was appropriate for robust and replicable estimation of model parameters [54]. Nevertheless, aspects such as the inclusion of moderate covariates, potential underlying collinearity, or missing data further contribute to the complexity of assessing the actual statistical power and the potential risk of overfitting of the models.

Centiles derived from cross-sectional brain charts have demonstrated to underestimate longitudinal brain changes, resulting in inaccurate predictors of longitudinal individual changes [55]. In this study, which includes extensive follow-up data, our objective was not to perform individualised age-related predictions, but to identify volumetric deviations associated with long-term cognitive and symptomatic outcomes in FEP. To account for residual age effects retained by the centiles, both age of inclusion and time were included as main effects in the models. However, longitudinal normative modelling was not performed due to the limited sample size. Future work will benefit from calibrating brain reference charts with longitudinal datasets [55]. This will be crucial for characterizing individual-level trajectories and for identifying subgroups that may account for clinical heterogeneity and differences in treatment response.

Conclusions

This study applied a normative modelling approach to demonstrate that FEP is characterised by regional decreases in cortical centiles. Centiles recovered to normative values during treatment but they were negatively affected by high doses of long-term medication. Similarly, improvements in cognitive abilities and symptomatology were positively associated with time, although were negatively influenced by prolonged medication use. Regions sensitive to symptomatology co-located with higher serotonin receptor densities and other neurobiological features. Collectively, these findings provide critical insights into the long-term interactions between cortical structure, treatment, medication, cognitive function, and symptom profiles.

Data and Code availability

498 All code and non-clinical data used to perform the analyses can be found at
499 https://github.com/RafaelRomeroGarcia/LongitudinalCentilesFEP/. Data from patients is
500 available upon request in accordance with ethical regulations. All statistical results are
501 provided in a supplementary Excel file.

502 **Acknowledgements**

503 We thank Agoston Mihalik, Golia Shafiei, Bratislav Misic, Victor Ortiz and Lifespan Brain Chart
504 Consortium for their contribution.

505 **Funding**

506 RRG is funded by the EMERGIA Junta de Andalucía program (EMERGIA20_00139), ERANET
507 Neuron JTC 2023 (ERP-2023-23684211), and the Plan de Consolidación (CNS2023-143647).
508 Both RRG and CAM, are funded by the *Plan de Generación de Conocimiento* from the Agencia
509 Estatal de Investigación (PID2021-122853OA-I00). JS is funded by the Psychosis Immune
510 Mechanism Stratified Medicine Study (PIMS), UK Medical Research Council, MR/S037675/1. All
511 research at the Department of Psychiatry in the University of Cambridge is supported by the
512 NIHR Cambridge Biomedical Research Centre (NIHR203312) and the NIHR Applied Research
513 Collaboration East of England. The views expressed are those of the author(s) and not
514 necessarily those of the NIHR or the Department of Health and Social Care

515 **Author Contributions**

516 C.A-M performed data curation, methodological design, data analysis, and drafted the
517 manuscript; N.G-S-M, R.A.I.B, L.D, M.A-N, P.S, A.P, M.M-C, M.C R, J.S, R.A-A, J.V-B, J.S, M.R-V,
518 B.C-F and R.R-G contributed to data acquisition, provided advice on data analysis, and
519 participated in writing and editing the manuscript. R.R.G. also contributed to
520 conceptualization, first manuscript draft, and supervision of the work. All authors approved
521 the submitted version of the manuscript.

522 **Competing interests**

523 RAIB and JS hold equity in and are directors of Centile Bioscience. All other authors declare
524 that they have no known competing interests.

525 ## REFERENCES

526 1 Voineskos AN, Jacobs GR, Ameis SH. Neuroimaging Heterogeneity in Psychosis:
527 Neurobiological Underpinnings and Opportunities for Prognostic and Therapeutic
528 Innovation. *Biological Psychiatry* 2020; **88**: 95–102.

2 Prakash J, Chatterjee K, Srivastava K, Chauhan VS. First-episode psychosis: How long does it last? A review of evolution and trajectory. *Ind Psychiatry J* 2021; **30**: 198–206.

3 Leucht S, Crippa A, Siafis S, Patel MX, Orsini N, Davis JM. Dose-Response Meta-Analysis of Antipsychotic Drugs for Acute Schizophrenia. *AJP* 2020; **177**: 342–53.

4 Oertel-Knöchel V, Knöchel C, Rotarska-Jagiela A, Reinke B, Prvulovic D, Haenschel C, *et al.* Association between Psychotic Symptoms and Cortical Thickness Reduction across the Schizophrenia Spectrum. *Cerebral Cortex* 2013; **23**: 61–70.

5 Crespo-Facorro B. Insular cortex abnormalities in schizophrenia: a structural magnetic resonance imaging study of first-episode patients. *Schizophrenia Research* 2000; **46**: 35–43.

6 Yildiz M, Borgwardt SJ, Berger GE. Parietal Lobes in Schizophrenia: Do They Matter? *Schizophr Res Treatment* 2011; **2011**: 581686.

7 Tordesillas-Gutierrez D, Ayesa-Arriola R, Delgado-Alvarado M, Robinson JL, Lopez-Morinigo J, Pujol J, *et al*. The right occipital lobe and poor insight in first-episode psychosis. *PLoS One* 2018; **13**: e0197715.

8 Del Re EC, Stone WS, Bouix S, Seitz J, Zeng V, Guliano A, *et al.* Baseline Cortical Thickness Reductions in Clinical High Risk for Psychosis: Brain Regions Associated with Conversion to Psychosis Versus Non-Conversion as Assessed at One-Year Follow-Up in the Shanghai-At-Risk-for-Psychosis (SHARP) Study. *Schizophr Bull* 2021; **47**: 562–74.

9 Cobia DJ, Smith MJ, Wang L, Csernansky JG. Longitudinal progression of frontal and temporal lobe changes in schizophrenia. *Schizophrenia Research* 2012; **139**: 1–6.

10 van Haren NEM, Hulshoff Pol HE, Schnack HG, Cahn W, Mandl RCW, Collins DL, *et al.* Focal gray matter changes in schizophrenia across the course of the illness: a 5-year follow-up study. *Neuropsychopharmacology* 2007; **32**: 2057–66.

11 Rodriguez-Perez N, Ayesa-Arriola R, Ortiz-García de la Foz V, Setien-Suero E, Tordesillas-Gutierrez D, Crespo-Facorro B. Long term cortical thickness changes after a first episode of non- affective psychosis: The 10 year follow-up of the PAFIP cohort. *Progress in Neuro-Psychopharmacology and Biological Psychiatry* 2021; **108**: 110180.

12 Bethlehem RAI, Seidlitz J, White SR, Vogel JW, Anderson KM, Adamson C, *et al.* Brain charts for the human lifespan. *Nature* 2022; **604**: 525–33.

13 Shan X, Uddin LQ, Xiao J, He C, Ling Z, Li L, *et al.* Mapping the Heterogeneous Brain Structural Phenotype of Autism Spectrum Disorder Using the Normative Model. *Biological Psychiatry* 2022; **91**: 967–76.

14 Marquand AF, Rezek I, Buitelaar J, Beckmann CF. Understanding Heterogeneity in Clinical Cohorts Using Normative Models: Beyond Case-Control Studies. *Biological Psychiatry* 2016; **80**: 552–61.

15 ENIGMA Clinical High Risk for Psychosis Working Group. Normative Modeling of Brain Morphometry in Clinical High Risk for Psychosis. *JAMA Psychiatry* 2024; **81**: 77–88.

16 Worker A, Berthert P, Lawrence AJ, Kia SM, Arango C, Dinga R, *et al.* Extreme deviations from the normative model reveal cortical heterogeneity and associations with negative symptom severity in first-episode psychosis from the OPTiMiSE and GAP studies. *Transl Psychiatry* 2023; **13**: 1–9.

17 Berthet P, Haatveit BC, Kjelkenes R, Worker A, Kia SM, Wolfers T, *et al.* A 10-Year Longitudinal Study of Brain Cortical Thickness in People with First-Episode Psychosis Using Normative Models. *Schizophrenia Bulletin* 2024; **51**: 95–107.

18 Padmanabhan JL, Tandon N, Haller CS, Mathew IT, Eack SM, Clementz BA, *et al.* Correlations Between Brain Structure and Symptom Dimensions of Psychosis in Schizophrenia, Schizoaffective, and Psychotic Bipolar I Disorders. *Schizophrenia Bulletin* 2015; **41**: 154–62.

19 Walton E, Hibar DP, van Erp TG, Potkin SG, Roiz-Santiañez R, Crespo-Facorro B, *et al.* Positive symptoms associate with cortical thinning in the superior temporal gyrus via the ENIGMA-Schizophrenia consortium. *Acta Psychiatr Scand* 2017; **135**: 439–47.

20 Walton E, Hibar DP, van Erp TGM, Potkin SG, Roiz-Santiañez R, Crespo-Facorro B, *et al.* Prefrontal cortical thinning links to negative symptoms in schizophrenia via the ENIGMA consortium. *Psychol Med* 2018; **48**: 82–94.

21 Vita A, De Peri L, Deste G, Barlati S, Sacchetti E. The Effect of Antipsychotic Treatment on Cortical Gray Matter Changes in Schizophrenia: Does the Class Matter? A Meta-analysis and Meta-regression of Longitudinal Magnetic Resonance Imaging Studies. *Biol Psychiatry* 2015; **78**: 403–12.

22 Goghari VM, Smith GN, Honer WG, Kopala LC, Thornton AE, Su W, *et al.* Effects of eight weeks of atypical antipsychotic treatment on middle frontal thickness in drug-naïve first-episode psychosis patients. *Schizophrenia Research* 2013; **149**: 149–55.

23 Bora E, Murray RM. Meta-analysis of cognitive deficits in ultra-high risk to psychosis and first-episode psychosis: do the cognitive deficits progress over, or after, the onset of psychosis? *Schizophr Bull* 2014; **40**: 744–55.

24 McCleery A, Nuechterlein KH. Cognitive impairment in psychotic illness: prevalence, profile of impairment, developmental course, and treatment considerations. *Dialogues Clin Neurosci* 2019; **21**: 239–48.

25 Fett A-KJ, Velthorst E, Reichenberg A, Ruggero CJ, Callahan JL, Fochtmann LJ, *et al.* Long-term Changes in Cognitive Functioning in Individuals With Psychotic Disorders: Findings From the Suffolk County Mental Health Project. *JAMA Psychiatry* 2020; **77**: 387–96.

26 Burgher B, Scott J, Cocchi L, Breakspear M. Longitudinal changes in neural gain and its relationship to cognitive control trajectory in young adults with early psychosis. *Transl Psychiatry* 2023; **13**: 1–9.

27 Gur RC, Calkins ME, Satterthwaite TD, Ruparel K, Bilker WB, Moore TM, *et al.* Neurocognitive Growth Charting in Psychosis Spectrum Youths. *JAMA Psychiatry* 2014; **71**: 366–74.

606 28 Husa AP, Moilanen J, Murray GK, Marttila R, Haapea M, Rannikko I, *et al.* Lifetime
607 antipsychotic medication and cognitive performance in schizophrenia at age 43 years in a
608 general population birth cohort. *Psychiatry Res* 2017; **247**: 130–8.

609 29 Hettwer MD, Larivière S, Park BY, van den Heuvel OA, Schmaal L, Andreassen OA, *et al.*
610 Coordinated cortical thickness alterations across six neurodevelopmental and psychiatric
611 disorders. *Nat Commun* 2022; **13**: 6851.

612 30 García-San-Martín N, Bethlehem RA, Mihalik A, Seidlitz J, Sebenius I, Alemán-Morrillo C, *et*
613 *al.* Molecular and micro-architectural mapping of abnormal gray matter developmental
614 trajectories in psychosis. 2023; : 2023.12.11.23299652.

615 31 Rodríguez-Sánchez JM, Setién-Suero E, Suárez-Pinilla P, Son JMV, Vázquez-Bourgon J,
616 López PG, *et al.* Ten-year course of cognition in first-episode non-affective psychosis
617 patients: PAFIP cohort. *Psychological Medicine* 2022; **52**: 770–9.

618 32 Gardner M, Shinohara RT, Bethlehem RAI, Romero-Garcia R, Warrier V, Dorfschmidt L, *et*
619 *al.* ComBatLS: A location- and scale-preserving method for multi-site image harmonization.
620 *bioRxiv* 2024; : 2024.06.21.599875.

621 33 Danivas V, Venkatasubramanian G. Current perspectives on chlorpromazine equivalents:
622 Comparing apples and oranges! *Indian J Psychiatry* 2013; **55**: 207–8.

623 34 Mesulam M-M, Mesulam M-M, editors. *Principles of behavioral and cognitive neurology*.
624 (2. ed.) Oxford Univ. Press, 2000.

625 35 Hansen JY, Shafiei G, Markello RD, Smart K, Cox SML, Nørgaard M, *et al.* Mapping
626 neurotransmitter systems to the structural and functional organization of the human
627 neocortex. *Nat Neurosci* 2022; **25**: 1569–81.

628 36 Dear R, Wagstyl K, Seidlitz J, Markello RD, Arnatkevičiūtė A, Anderson KM, *et al.* Cortical
629 gene expression architecture links healthy neurodevelopment to the imaging,
630 transcriptomics and genetics of autism and schizophrenia. *Nat Neurosci* 2024; **27**: 1075–
631 86.

632 37 Mihalik A, Chapman J, Adams RA, Winter NR, Ferreira FS, Shawe-Taylor J, *et al.* Canonical
633 Correlation Analysis and Partial Least Squares for Identifying Brain-Behavior Associations:
634 A Tutorial and a Comparative Study. *Biol Psychiatry Cogn Neurosci Neuroimaging* 2022; **7**:
635 1055–67.

636 38 Thompson PM, Jahanshad N, Ching CRK, Salminen LE, Thomopoulos SI, Bright J, *et al.*
637 ENIGMA and global neuroscience: A decade of large-scale studies of the brain in health
638 and disease across more than 40 countries. *Transl Psychiatry* 2020; **10**: 100.

639 39 Pantelis C, Yücel M, Wood SJ, Velakoulis D, Sun D, Berger G, *et al.* Structural brain imaging
640 evidence for multiple pathological processes at different stages of brain development in
641 schizophrenia. *Schizophr Bull* 2005; **31**: 672–96.

642 40 Woods BT. Is Schizophrenia a Progressive Neurodevelopmental Disorder? Toward a
643 Unitary Pathogenetic Mechanism. *AJP* 1998; **155**: 1661–70.

41 Haijma SV, Van Haren N, Cahn W, Koolschijn PCMP, Hulshoff Pol HE, Kahn RS. Brain Volumes in Schizophrenia: A Meta-Analysis in Over 18 000 Subjects. *Schizophrenia Bulletin* 2013; **39**: 1129–38.

42 Gassó P, Mas S, Molina O, Bernardo M, Lafuente A, Parellada E. Neurotoxic/neuroprotective activity of haloperidol, risperidone and paliperidone in neuroblastoma cells. *Progress in Neuro-Psychopharmacology and Biological Psychiatry* 2012; **36**: 71–7.

43 Fusar-Poli P, Smieskova R, Kempton MJ, Ho BC, Andreasen NC, Borgwardt S. Progressive brain changes in schizophrenia related to antipsychotic treatment? A meta-analysis of longitudinal MRI studies. *Neurosci Biobehav Rev* 2013; **37**: 1680–91.

44 Zipparo L, Whitford TJ, Redoblado Hodge MA, Lucas S, Farrow TFD, Brennan J, *et al.* Investigating the neuropsychological and neuroanatomical changes that occur over the first 2-3 years of illness in patients with first-episode schizophrenia. *Prog Neuropsychopharmacol Biol Psychiatry* 2008; **32**: 531–8.

45 Zabala A, Eguiluz JI, Segarra R, Enjuto S, Ezcurra J, Elizagarate E, *et al.* Course of cognitive functioning in first-episode psychosis: a comparison between schizophrenia and non schizophrenia psychosis. *Rev Psiquiatr Salud Ment* 2008; **1**: 18–25.

46 Kawai N, Yamakawa Y, Baba A, Nemoto K, Tachikawa H, Hori T, *et al.* High-dose of multiple antipsychotics and cognitive function in schizophrenia: The effect of dose-reduction. *Progress in Neuro-Psychopharmacology and Biological Psychiatry* 2006; **30**: 1009–14.

47 Fusar-Poli P, Papanastasiou E, Stahl D, Rocchetti M, Carpenter W, Shergill S, *et al.* Treatments of Negative Symptoms in Schizophrenia: Meta-Analysis of 168 Randomized Placebo-Controlled Trials. *Schizophr Bull* 2015; **41**: 892–9.

48 Austin SF, Mors O, Budtz-Jørgensen E, Secher RG, Hjorthøj CR, Bertelsen M, *et al.* Long-term trajectories of positive and negative symptoms in first episode psychosis: A 10 year follow-up study in the OPUS cohort. *Schizophrenia Research* 2015; **168**: 84–91.

49 Grinchii D, Dremencov E. Mechanism of Action of Atypical Antipsychotic Drugs in Mood Disorders. *Int J Mol Sci* 2020; **21**: 9532.

50 Celada P, Puig MV, Amargós-Bosch M, Adell A, Artigas F. The therapeutic role of 5-HT1A and 5-HT2A receptors in depression. *J Psychiatry Neurosci* 2004; **29**: 252–65.

51 Bernstein H-G, Steiner J, Guest PC, Dobrowolny H, Bogerts B. Glial cells as key players in schizophrenia pathology: recent insights and concepts of therapy. *Schizophr Res* 2015; **161**: 4–18.

52 Marek S, Tervo-Clemmens B, Calabro FJ, Montez DF, Kay BP, Hatoum AS, *et al.* Reproducible brain-wide association studies require thousands of individuals. *Nature* 2022; **603**: 654–60.

53 Study design features increase replicability in brain-wide association studies | Nature. (https://www.nature.com/articles/s41586-024-08260-9).

54 Maas CJM, Hox JJ. Sufficient Sample Sizes for Multilevel Modeling. *Methodology: European Journal of Research Methods for the Behavioral and Social Sciences* 2005; **1**: 86–92.

55 Di Biase MA, Tian YE, Bethlehem RAI, Seidlitz J, Alexander-Bloch AF, Yeo BTT, *et al.* Mapping human brain charts cross-sectionally and longitudinally. *Proc Natl Acad Sci U S A* 2023; **120**: e2216798120.